Protalix BioTherapeutics, Inc. PLX
Set alert
2.59 USD -0.02 -0.77%
At close · Oct 30
2.56 -0.03 -1.16%
After hours · Oct 30, 5:05 PM ET
2.57 Day range 2.62
1.67 52-week range 3.15
- YTD
- +43.89%
- 1 year
- +14.60%
- Open
- 2.60
- Prev close
- 2.61
- Mkt cap
- 208.68M
- Vol
- 249.29K
- Avg vol
- 800.78K
- EPS
- 0.23
- P/E
- 11.26
- Div yield
- 0.00%
More statistics
- Low
- 2.57
- High
- 2.62
- Forward P/E
- 2.79
- Beta
- 0.67
- Short ratio
- 22.71
- Inst. own
- 5.20%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.43
- 200-d avg
- 1.21
- 1y target
- 14.00
Financial health
Altman Z-Score
0.74 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
4 / 9 Average
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
A-4 / 5 overall
- DCF 1
- Return on Equity 5
- Return on Assets 5
- Debt / Equity 3
- P/E 3
- P/B 3
Valuation
P/E -21.4×
FY 2016 5y median -1.3× FY 2025
P/S 2.7×
FY 2016 5y median 1.8× FY 2025
P/B 2.9×
FY 2016 5y median 2.9× FY 2025
P/FCF -10.4×
FY 2016 5y median -3.1× FY 2025
EV/EBITDA -45.7×
FY 2016 5y median -1.6× FY 2025
EV/Sales 2.6×
FY 2016 5y median 1.9× FY 2025
FCF Yield -9.6%
FY 2016 5y median -9.6% FY 2025
Profitability
Gross Margin 47.8%
FY 2016 5y median 57.4% FY 2025
Operating Margin -10.4%
FY 2016 5y median -10.4% FY 2025
Net Margin -12.5%
FY 2016 5y median -12.5% FY 2025
ROE -13.7%
FY 2016 5y median 24.8% FY 2025
ROIC -9.6%
FY 2016 5y median -9.6% FY 2025
ROA -8.0%
FY 2016 5y median -8.0% FY 2025
Growth (YoY)
Revenue -1.2%
FY 2016 FY 2025
Operating Income -240.4%
FY 2016 FY 2025
EPS (diluted) -329.8%
FY 2016 FY 2025
Free Cash Flow -284.4%
FY 2016 FY 2025
Financial Health
Current Ratio 2.5×
FY 2016 5y median 1.9× FY 2025
Quick Ratio 1.5×
FY 2016 5y median 1.3× FY 2025
Debt / Equity 0.2×
FY 2016 5y median 0.1× FY 2025
Net Debt / EBITDA 2.2×
FY 2016 5y median 0.3× FY 2025
Interest Coverage -4.6×
FY 2016 5y median -2.7× FY 2025
Dividends
Dividend Yield 0.0%
FY 2016 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2016 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31